SCHEMBL2195495

SCHEMBL2195495

Cn1c(-c2ccccc2)c(-c2ccccc2)n(C)c1=[Pt].IN(I)C1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
CNR1 P21554 1/20 0.34
GBA1 P04062 4/20 0.34
LMNA P02545 2/20 0.34
TSHR P16473 2/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.32
HTR2A P28223 3/20 0.32
HTR2C P28335 3/20 0.32
KCNH2 Q12809 1/20 0.32
DRD2 P14416 2/20 0.32
HPGD P15428 2/20 0.31
HSD17B10 Q99714 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194479 0.98 ALDH1A1 (0.38) ALDH1A1CNR1GBA1LMNATSHR
SCHEMBL2196175 0.94 TSHR (0.35) ALDH1A1CNR1LMNATSHRPOLB
SCHEMBL2192956 0.85 DRD2 (0.35) ALDH1A1LMNATSHRPOLBMAPK1
SCHEMBL2194623 0.84 ALDH1A1 (0.38) ALDH1A1CNR1GBA1LMNATSHR
SCHEMBL2197224 0.84 ALDH1A1 (0.38) ALDH1A1CNR1GBA1LMNATSHR
SCHEMBL2193811 0.83 LMNA (0.35) ALDH1A1LMNATSHRKDM4EMEN1
SCHEMBL2194455 0.81 KMT2A (0.37) ALDH1A1LMNATSHRMAPK1KDM4E
SCHEMBL2197553 0.81 DDB1 (0.33) ALDH1A1LMNAKMT2AHPGDGLA
SCHEMBL2196848 0.79 LMNA (0.33) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL2194303 0.79 LMNA (0.33) ALDH1A1LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALDH1A1 1989/4885CNR1 278/4885GBA1 1161/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALDH1A1 1989/4885CNR1 278/4885GBA1 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.